Sanford Burnham Prebys study: Molecular differences help explain higher breast cancer mortality in Black women

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.

April 25, 2025

Vol.51 No.16

In Brief

Hope Rugo named director of City of Hope’s Women’s Cancers Program

Hope S. Rugo has joined City of Hope to lead its Women’s Cancers Program throughout the organization and breast medical oncology division section.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Researchers explore adapted Argentine tango dance therapy for cancer survivors at Ohio State

Adapted Argentine tango dance therapy is helping some breast cancer survivors regain natural balance and sensation after experiencing neuropathy, a common side effect of chemotherapy treatment. Expansion of a new clinical study will look further at how this musical movement intervention can “rewire” the brain to improve function after chemotherapy-related nerve changes.

April 18, 2025

Vol.51 No.15

In Brief

Less Radical, a podcast about Bernie Fisher, nominated for two Webby Awards

Less Radical, a documentary podcast that tells story of Bernie Fisher, a pioneering surgeon-scientist who redefined breast cancer treatment, was nominated for Best Podcast - Documentary and Best Indie Podcast – Limited Run in the 29th Annual Webby Awards.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Mass General study: Screenings for breast and colorectal cancer 4x higher than lung cancer

Although lung cancer screening is recommended in the U.S. for certain individuals with a history of smoking, only 18% of eligible individuals in the U.S. get screened.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.

April 04, 2025

Vol.51 No.13

Sanford Burnham Prebys study: Molecular differences help explain higher breast cancer mortality in Black women

YOU MAY BE INTERESTED IN

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer

Hope Rugo named director of City of Hope’s Women’s Cancers Program

Researchers explore adapted Argentine tango dance therapy for cancer survivors at Ohio State

Less Radical, a podcast about Bernie Fisher, nominated for two Webby Awards

Mass General study: Screenings for breast and colorectal cancer 4x higher than lung cancer

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

Renew today!

Subscriber content

Never miss an issue!

Login